TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct preplanned interim analysis. Topline data from the interim analysis should be available by the end of this year, which is also when the company expects the study will conclude. “Enrolling patients in an orphan disease trial is always a challenge, and that’s why we are thrilled with the rate of enrollment in this potentially pivotal study,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The robust interest and enthusiasm among our investigators and patients reflect the pressing need to develop treatment options for patients with GBM. Addressing this devastating disease continues to be the driving force for our team.”

In addition, the company announced that Climaco will be featured in a live, moderated fireside chat on Benzinga’s upcoming Virtual Biotech Conference. The conference is slated for Aug. 3, 2023; the fireside chat will begin at 11:35 a.m. ET. Benzinga’s Virtual Biotech Conference spotlights biotech leaders and features the hottest companies in the biotech space today.

To view the fireside chat, visit https://ibn.fm/bDZmF

To view the full press releases, visit https://ibn.fm/05vzR and https://ibn.fm/LHjfM

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork.

Alex Pearon

Share
Published by
Alex Pearon

Recent Posts

TinyGemsBreaks – PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Reports FY 2025 Results, Highlights Transition to Independent Power Producer Model 

Disseminated on behalf of PowerBank Corporation PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) reported…

2 days ago

TinyGemsBreaks – Bollinger Innovations, Inc. (NASDAQ: BINI) Signs Agreement to Supply Mullen EVs for FedEx ISP Fleets

Bollinger Innovations (NASDAQ: BINI), an electric vehicle manufacturer, announced it has signed an agreement with…

2 days ago

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sets Standard in High-Performance E-Boat Space

Vision Marine Technologies Inc. (NASDAQ: VMAR) was featured in a recent article that discusses its positioning…

3 days ago

TinyGemsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Prices $344.4 Million in PIPEs to Launch Digital Asset Treasury Strategy

Predictive Oncology (NASDAQ: POAI) announced the pricing of two concurrent private placement transactions totaling approximately…

4 days ago

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Launches International Gaming Platform

SEGG Media (NASDAQ: SEGG, LTRYW), a global sports, entertainment, and gaming conglomerate, announced the official…

1 week ago

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Signs LOI to Acquire Racing Women Assets, Expand Into Women’s Motorsport

SEGG Media (NASDAQ: SEGG, LTRYW) announced that its subsidiary Sports.com Media Group Ltd has signed…

1 week ago